Department of Medicine, University of Colorado Denver, School of Medicine, Aurora, CO, 80045, USA.
Department of Medicine, University of Alabama at Birmingham, School of Medicine, Birmingham, AL, 35294, USA.
Nat Commun. 2018 Dec 18;9(1):5363. doi: 10.1038/s41467-018-07768-9.
The gain-of-function MUC5B promoter variant rs35705950 is the dominant risk factor for developing idiopathic pulmonary fibrosis (IPF). Here we show in humans that MUC5B, a mucin thought to be restricted to conducting airways, is co-expressed with surfactant protein C (SFTPC) in type 2 alveolar epithelia and in epithelial cells lining honeycomb cysts, indicating that cell types involved in lung fibrosis in distal airspace express MUC5B. In mice, we demonstrate that Muc5b concentration in bronchoalveolar epithelia is related to impaired mucociliary clearance (MCC) and to the extent and persistence of bleomycin-induced lung fibrosis. We also establish the ability of the mucolytic agent P-2119 to restore MCC and to suppress bleomycin-induced lung fibrosis in the setting of Muc5b overexpression. Our findings suggest that mucociliary dysfunction might play a causative role in bleomycin-induced pulmonary fibrosis in mice overexpressing Muc5b, and that MUC5B in distal airspaces is a potential therapeutic target in humans with IPF.
MUC5B 启动子变异 rs35705950 是导致特发性肺纤维化(IPF)的主要风险因素。在这里,我们在人类中表明,MUC5B 是一种被认为仅限于传导气道的粘蛋白,与 II 型肺泡上皮细胞和蜂窝状囊肿衬里的表面活性蛋白 C(SFTPC)共同表达,表明参与远端气腔肺纤维化的细胞类型表达 MUC5B。在小鼠中,我们证明了支气管肺泡上皮细胞中 Muc5b 的浓度与黏液纤毛清除(MCC)受损以及博莱霉素诱导的肺纤维化的程度和持续时间有关。我们还确定了粘液溶解剂 P-2119 在 Muc5b 过表达的情况下恢复 MCC 和抑制博莱霉素诱导的肺纤维化的能力。我们的研究结果表明,粘液纤毛功能障碍可能在 Muc5b 过表达的小鼠的博莱霉素诱导的肺纤维化中起因果作用,并且远端气腔中的 MUC5B 是 IPF 患者的潜在治疗靶点。